LOGIN  |  REGISTER
Cue Biopharma
Assertio

Insmed To Present at Three March Conferences

February 29, 2024 | Last Trade: US$69.49 0.12 -0.17

BRIDGEWATER, N.J., Feb. 29, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences:

  • The TD Cowen 44th Annual Health Care Conference in Boston on Monday, March 4, 2024, at 2:50 p.m. ET in a fireside chat
  • The Leerink Partners Global Biopharma Conference 2024 in Miami on Tuesday, March 12, 2024, at 1:00 p.m. ET in a fireside chat
  • The Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024, at 4:35 p.m. ET in a fireside chat

Each fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Each webcast will be archived for a period of 30 days following the conclusion of the live event.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations throughout the United States, Europe, and Japan. Visit www.insmed.com to learn more.

Contact:

Investors:

Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
This email address is being protected from spambots. You need JavaScript enabled to view it.

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB